Overview

CP-675,206 In Patients With Advanced Melanoma

Status:
Completed

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Ipilimumab
Tremelimumab